
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Tyra Biosciences Inc (TYRA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TYRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $30.14
1 Year Target Price $30.14
6 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.58% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 569.00M USD | Price to earnings Ratio - | 1Y Target Price 30.14 |
Price to earnings Ratio - | 1Y Target Price 30.14 | ||
Volume (30-day avg) 8 | Beta 1.08 | 52 Weeks Range 6.42 - 29.60 | Updated Date 08/15/2025 |
52 Weeks Range 6.42 - 29.60 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.63 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.53 | Actual -0.47 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19% | Return on Equity (TTM) -27.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 256183493 | Price to Sales(TTM) - |
Enterprise Value 256183493 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.95 | Shares Outstanding 53178000 | Shares Floating 14570237 |
Shares Outstanding 53178000 | Shares Floating 14570237 | ||
Percent Insiders 3.69 | Percent Institutions 110.41 |
Upturn AI SWOT
Tyra Biosciences Inc
Company Overview
History and Background
Tyra Biosciences, Inc. is a precision oncology company focused on developing next-generation therapies to overcome tumor resistance and improve outcomes for cancer patients. Founded in 2018, they leverage their SNAP platform to design selective therapies. They went public in 2020.
Core Business Areas
- Precision Oncology Drug Development: Developing small molecule drugs targeting cancer drivers and resistance mechanisms.
- SNAP Platform: Utilizing their SNAP platform to rapidly and precisely design novel cancer therapies.
Leadership and Structure
The leadership team includes Todd Harris (CEO). The company is structured with research, development, and clinical operations divisions.
Top Products and Market Share
Key Offerings
- TYRA-300 (pan-FGFR inhibitor): An investigational pan-FGFR inhibitor designed to address acquired resistance mutations in FGFR-altered cancers. Currently in clinical trials. No market share data available as it is pre-commercial. Competitors include existing FGFR inhibitors and other companies developing similar therapies.
- TYRA-200 (RET inhibitor): An investigational RET inhibitor that addresses selectivity and overcomes clinical resistance. Currently in clinical trials. No market share data available as it is pre-commercial. Competitors include Eli Lilly's Retevmo (selpercatinib) and Blueprint Medicines' Gavreto (pralsetinib).
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market driven by increasing cancer incidence and advances in treatment options, particularly precision oncology.
Positioning
Tyra is positioned as a precision oncology company focused on overcoming drug resistance with its SNAP platform, which could provide a competitive advantage over companies developing less selective or less adaptable therapies.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be hundreds of billions of dollars. Tyra is positioned to capture a portion of this TAM with its pipeline of targeted therapies addressing specific resistance mechanisms.
Upturn SWOT Analysis
Strengths
- SNAP platform technology
- Focus on drug resistance
- Experienced leadership team
- Strong intellectual property portfolio
- Targeted pipeline
Weaknesses
- Early-stage clinical pipeline
- Dependence on clinical trial success
- Limited commercialization experience
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of SNAP platform to other therapeutic areas
- Positive clinical trial results
- FDA approval and commercialization of lead candidates
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- LLY
- BMY
- ROG.SW
Competitive Landscape
Tyra differentiates itself through its SNAP platform. Success depends on clinical data compared to the above competitor's already FDA approved products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is still in the early stages of development.
Future Projections: Future growth is dependent on clinical trial success and eventual commercialization of its pipeline candidates.
Recent Initiatives: Focus on advancing TYRA-300 and TYRA-200 through clinical trials, expanding SNAP platform capabilities.
Summary
Tyra Biosciences is an early-stage precision oncology company with a promising SNAP platform and targeted pipeline. Its success heavily relies on the outcome of ongoing clinical trials. While the SNAP platform provides a competitive edge, the company faces challenges typical of biotech startups, including high cash burn and clinical development risks. Investors should monitor clinical data and partnerships closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tyra Biosciences Inc. investor relations website
- SEC filings
- Analyst reports
- Company press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tyra Biosciences Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-09-15 | Co-Founder, President, CEO, Secretary, Treasurer & Director Dr. Todd Harris Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://tyra.bio |
Full time employees 60 | Website https://tyra.bio |
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.